Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2).
7 Mins
1st
December
2022
EMJ Gastroenterology 8 [Suppl 1] . 2019
Latest articles
All articles
14 Mins
4th
November
2022
The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance